Delving into the Latest Updates on AVN-999 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

AVPR1A

Mechanism

AVPR1A antagonists(Vasopressin V1a receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Brain Injuries, Traumatic

Originator Organization

Azevan Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Lehigh University

Northeastern University

Azevan Pharmaceuticals, Inc.

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Arginine vasopressin (AVP) is a chemical signal in the brain that influences cerebral vascular resistance and brain water permeability. Increases in AVP contribute to the pathophysiology of brain edema following traumatic brain injury (TBI). These effects are mediated through AVP V1a receptors that are expressed in cortical and subcortical brain areas. This exploratory study characterizes the effects of a novel, V1a receptor antagonist, AVN576, on behavioral and magnetic resonance imaging (MRI) measures after severe TBI. Male Sprague Dawley rats were impacted twice producing contusions in the forebrain, putative cerebral edema, and cognitive deficits. Rats were treated with AVN576 after initial impact for 5 days and then tested for changes in cognition. MRI was used to assess brain injury, enlargement of the ventricles, and resting state functional connectivity. Vehicle treated rats had significant deficits in learning and memory, enlarged ventricular volumes, and hypoconnectivity in hippocampal circuitry. AVN576 treatment eliminated the enlargement of the lateral ventricles and deficits in cognitive function while increasing connectivity in hippocampal circuitry. These data corroborate the extensive literature that drugs selectively targeting the AVP V1a receptor could be used to treat TBI in the clinic.

100 Deals associated with AVN-999

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Injuries, Traumatic	Preclinical	US	Azevan Pharmaceuticals, Inc.	-
Brain Injuries, Traumatic	Preclinical	US	Lehigh University	-
Brain Injuries, Traumatic	Discovery	US	Northeastern University	-